Top Page
Alphamab Oncology
(9966)
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
Alphamab Oncology Business Overview & Revenue Model
Alphamab Oncology Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 640.08M | 218.77M | 166.84M | 146.02M | 0.00 |
| Gross Profit | 579.77M | 163.54M | 122.64M | 142.99M | 0.00 |
| EBITDA | 156.79M | -129.30M | -391.83M | -358.13M | -390.47M |
| Net Income | 166.34M | -210.59M | -325.72M | -412.42M | -427.77M |
Balance Sheet | |||||
| Total Assets | 2.24B | 2.14B | 2.12B | 2.71B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.57B | 1.41B | 1.35B | 1.99B | 2.06B |
| Total Debt | 185.96M | 257.08M | 345.39M | 637.27M | 222.81M |
| Total Liabilities | 409.87M | 465.00M | 559.86M | 834.80M | 366.44M |
| Stockholders Equity | 1.83B | 1.67B | 1.56B | 1.87B | 2.27B |
Cash Flow | |||||
| Free Cash Flow | 190.56M | -239.02M | -429.96M | -478.72M | -438.00M |
| Operating Cash Flow | 212.34M | -202.84M | -300.31M | -320.60M | -347.18M |
| Investing Cash Flow | -92.93M | -18.11M | 850.76M | 574.26M | -1.52B |
| Financing Cash Flow | -98.96M | 218.07M | -310.90M | 363.90M | 186.58M |
Alphamab Oncology Technical Analysis
Alphamab Oncology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$11.44B | 60.09 | 6.73% | ― | 23.37% | ― | |
61 Neutral | HK$10.52B | 57.57 | 9.52% | ― | 185.36% | ― | |
60 Neutral | HK$19.40B | 4.63 | -1.43% | 3.30% | 11.28% | -16.47% | |
58 Neutral | HK$14.40B | ― | -12.74% | ― | -76.58% | -4.90% | |
57 Neutral | HK$18.92B | ― | -21.42% | ― | 240.05% | -140.09% | |
55 Neutral | HK$3.75B | ― | -75.64% | ― | 42.21% | 29.52% | |
54 Neutral | HK$10.41B | 428.97 | 2.28% | ― | -57.55% | -87.49% |
Alphamab Oncology Corporate Events
Alphamab Oncology announced a positive profit alert, expecting a profit of not less than RMB20.0 million for the first half of 2025, reversing a loss of approximately RMB44.9 million in the same period of 2024. This turnaround is attributed to milestone revenue from three licensed collaborations and sales revenue from a commercialized product, indicating a significant improvement in the company’s financial performance and market positioning.
Alphamab Oncology has announced that its board of directors will meet on August 28, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational progress, impacting stakeholders’ expectations and the company’s market positioning.
Alphamab Oncology has announced a technology development collaboration with Suzhou Alphamab, a connected transaction under the Hong Kong Stock Exchange rules. This agreement involves Suzhou Alphamab providing technology development services for Alphamab’s bispecific antibody-drug conjugate candidate, including developing production processes and preparing samples for regulatory filings. The partnership is valued at RMB10,240,000 and is expected to enhance Alphamab’s capabilities in bringing new cancer treatments to market, potentially strengthening its position in the biopharmaceutical industry.
Alphamab Oncology announced that its Investigational New Drug application for JSKN022, a novel bispecific antibody-drug conjugate targeting PD-L1 and integrin αv β6, has been accepted by China’s Center for Drug Evaluation. This development marks a significant step in the company’s efforts to introduce innovative cancer therapies, particularly for tumors resistant to existing PD-1/PD-L1 inhibitors. JSKN022, leveraging proprietary technology, could potentially offer new treatment options for challenging cancers such as non-small cell lung cancer and colorectal cancer.
Alphamab Oncology announced that its drug JSKN003 has received approval from the U.S. FDA to begin a phase II clinical study for treating platinum-resistant ovarian cancer not restricted by HER2 expression. This approval is a significant milestone in Alphamab’s global development strategy, enhancing its competitive position in oncology therapeutics. The study will assess the safety and efficacy of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, and determine the recommended phase III dose. This development is expected to strengthen Alphamab’s innovative pipeline and impact its stakeholders positively.
Alphamab Oncology announced that its drug JSKN003 has been granted Orphan Drug Designation by the U.S. FDA for treating gastric cancer and gastroesophageal junction cancer. This designation will support Alphamab’s efforts in research, development, and commercialization in the U.S., potentially offering benefits like funding, tax credits, and market exclusivity. The announcement marks a significant step in addressing the global health challenge posed by these cancers and enhances Alphamab’s position in the oncology sector.
Alphamab Oncology announced an increase in shareholding by its directors and senior management, who purchased 900,000 shares between July 14 and July 16, 2025, reflecting their confidence in the company’s growth prospects. Additionally, CEO Dr. Xu Ting exercised 9,005,890 options under the company’s Pre-IPO Share Option Plan I, further demonstrating strong belief in the company’s long-term investment value. These actions comply with relevant laws and regulations, maintaining a sufficient public float of shares.
Alphamab Oncology has established a Nomination Committee to enhance its corporate governance structure. The committee will be responsible for reviewing the board’s composition, identifying qualified candidates for directorships, and ensuring board diversity. This move is expected to strengthen the company’s strategic direction and improve stakeholder confidence.
Alphamab Oncology announced changes in its board of directors, with the resignation of Dr. Guo Zijian and Mr. Wei Kevin Cheng as independent non-executive directors, effective June 30, 2025, due to personal and work commitments. The company has appointed Ms. Wong Yan Ki Angel and Dr. Gao Xiang as new independent non-executive directors, bringing extensive experience in accounting, corporate finance, and capital markets, which could positively impact Alphamab’s strategic direction and governance.
Alphamab Oncology announced that all proposed resolutions at their Annual General Meeting on June 12, 2025, were approved by shareholders. Key resolutions included the approval of financial statements, granting mandates for share repurchase and issuance, and the re-election of directors, indicating strong shareholder support and potentially enhancing the company’s strategic flexibility and governance.
Alphamab Oncology announced the completion of a share placing by its controlling shareholder, involving 14,600,000 shares, which represents approximately 1.51% of the company’s issued share capital. This transaction, executed at HK$8.05 per share, adjusts the shareholding distribution, with the Vendor now holding 31.0% of shares. This move is likely to impact the company’s market positioning and shareholder dynamics.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced research updates for its drug JSKN003, presented at the 2025 ASCO Annual Meeting. The updates highlight the drug’s efficacy and safety in treating advanced solid tumors, including platinum-resistant ovarian cancer and heavily pretreated HER2-positive breast cancer. The studies show promising results, with significant tumor shrinkage and manageable safety profiles, positioning JSKN003 as a potential treatment option in ongoing phase III trials.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its controlling shareholder, Rubymab Ltd., has entered into a share placing agreement with Morgan Stanley & Co. International plc to sell 14,600,000 existing shares, representing approximately 1.51% of the company’s total issued share capital. This transaction is expected to slightly reduce Rubymab Ltd.’s stake in the company from 32.5% to 31.0%, potentially impacting the company’s shareholder structure and market perception.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced the grant of 120,000 award shares under its Restricted Share Award Scheme to three directors, including one non-executive and two independent non-executive directors. This move is part of the company’s strategy to reward the directors for their contributions and align their interests with the company’s goals. The shares will vest over 24 months and do not have performance targets, which the Remuneration Committee believes is consistent with market practices and the company’s remuneration policy.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced its upcoming Annual General Meeting scheduled for June 12, 2025, in Suzhou, China. The meeting will address several key resolutions, including the approval of financial statements and the authorization for directors to repurchase shares and issue additional shares. These resolutions are expected to impact the company’s operational strategies and shareholder value, reflecting its commitment to maintaining a strong market position and enhancing shareholder returns.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.